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1058Acute Gastrointestinal Graft-versus-Host Disease in
Pediatric Patients: Serum Albumin on Day 5 from
Initiation of Therapy Correlates with Nonrelapse
Mortality and Overall Survival
Evgenios Goussetis,1 Anna Paisiou,1 Vasiliki Kitra,1 Ioulia Peristeri,1 George Vessalas,1
Kaliopi Stefanaki,2 Ioanna Panayotou,3 Konstantina Giamaiou,1 Eleftheria Kontou,1
Margaret Kitzoni,1 Maria N. Dimopoulou,1 Savvas Karkelis,3 Yota Kafritsa,3
Eleni Rapsomaniki,4 Ioannis Papassotiriou,5 Panagiotis Tsirigotis,6
Eleftheria Roma,3 Stelios Graphakos1The aim of the present study was to identify factors associated with the risk of development of gastrointes-
tinal acute graft-versus-host disease (GI-aGVHD), as well as to evaluate the impact of various baseline param-
eters on response to treatment, nonrelapse mortality (NRM), and overall survival (OS) in pediatric patients
with GI-aGVHD after allogeneic hematopoietic stem cell transplantation (allo-SCT). We retrospectively an-
alyzed 300 pediatric patients who underwent allo-SCT from HLA-matched related or volunteer unrelated
donors in our institution. GI tract involvement was observed in 46 out of 133 patients with aGVHD grade
II-IV. Severe aGVHD (grade III-IV) was more frequently observed among patients with GI-aGVHD in com-
parison with patients without GI involvement (P\ .001). Treatment with steroids resulted in durable re-
sponses in 22/46 patients; 14 additional patients responded to salvage therapy, whereas 10 were
refractory to all treatments administered. Using Cox regression analysis, we observed that serum albumin
level $3 mg/dL on day 5 after the initiation of therapy with steroids was statistically significantly associated
with decreased hazard of NRM and improved OS (P 5 .021 and P 5 .026, respectively). In our study, serum
albumin level, early (1 day 5) after the onset of steroids in patients with GI-aGVHD, was a predictor of treat-
ment outcome. Prospective randomized trials need to be performed to verify the predictive significance of
serum albumin and the need for early intensification of immunosuppressive treatment.
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both adults and children. Although aGVHD was
thought to occur less often in pediatric recipients of
HSCT than in adult HSCT recipients, more recent
large pediatric transplant studies report rates of grade
II-IV aGVHD ranging from 28% to 56%, similar to
those observed in adults [1-3]. Many variables
including donor age, type of donor, source of the
stem cells, and HLA disparity are significantly
associated with the incidence of aGVHD [4,5]. Skin,
liver, and gastrointestinal (GI) tract are the main
targets of aGVHD. Approximately 80% and 50% of
patients with aGVHD will develop skin and GI tract
involvement, respectively [6,7].
Simple clinical or laboratory parameters, such as
serum level of bilirubin and the volume of diarrhea,
that parallel the extent of involvement in different or-
gans have been used for the grading of aGVHD.Grad-
ing systems help in the stratification of patients in to
groups with different prognosis and provide a rough
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tality (NRM), and overall survival (OS) [8,9].
GI-aGVHD is a dynamic process that potentially
can affect every segment of the alimentary tract; how-
ever, terminal ileum and colon are the most often in-
volved sites [10]. GI-aGVHD present with a variety
of symptoms, such as anorexia, nausea, vomiting, wa-
tery diarrhea, intestinal bleeding, abdominal pain,
etc. None of these symptoms is aGVHD specific, and
exclusion of other entities with a similar presentation,
such as infection or mucositis, is mandatory [11,12].
Grading of skin and liver aGVHD is easily repro-
ducible and based on clinical examination and simple
laboratory tests. In contrast, staging of GI-aGVHD
requires estimation of diarrhea volume, and the degree
of severity is dependent on total daily stool amount per
kilogram of body weight [13]. However we, like many
others, consider that estimation of the severity of in-
testinal inflammation, based on total daily stool vol-
ume is oversimplistic [14,15]. It is well known that
the amount of stool is dependent on many other
factors such as type and quantity of nutrition, use of
opioids, administration of antimotility agents, etc.,
and does not necessarily reflect the severity of
intestinal pathology. Moreover, there is sometimes a
significant lag time between termination of intestinal
inflammation, and resolution of diarrhea, making
stool volume an unreliable criterion for the
definition of steroid refractory aGVHD.
Although serum levels of inflammatory cytokines
such as tunor necrosis factor (TNF)-a, as well as
many other biomarkers, have been statistically associ-
ated with incidence of aGVHD, their prognostic
significance as predictors of response to initial treat-
ment, needs to be further studied [16-18]. Severe
colonic crypt loss in histologic samples at the time of
diagnosis of GI-aGVHD is the only marker that has
been associated with refractoriness to steroid therapy
and increased NRM [19]. However, gastrointestinal
endoscopy and intestinal mucosal biopsies in children
are not part of daily clinical practice because of con-
cerns regarding the safety of the procedure.
In the present study, we retrospectively analyzed the
incidence and the risk factors for GI-aGVHD develop-
ment after allo-HSCT in a cohort of 300 consecutively
treated patients at a single institution.Moreover, we an-
alyzed the association of various clinical and laboratory
parameters present at the onset or early after initiation
of treatment for GI-aGVHD, with response rates after
first line treatment, NRM, and OS.DESIGN AND METHODS
Patient Characteristics
We reviewed the medical records of all pediatric
patients who underwent allo-HSCT for bothmalignant and nonmalignant diseases at the Aghia So-
phia Children’s hospital, Athens, Greece, between
May 1994 andMay 2008. Only patients who died prior
to infusion of the graft were excluded from our retro-
spective analysis. Patient and transplant characteristics
are shown in Table 1. This retrospective study was ap-
proved by the Ethics in Human Research Committee
of the Aghia Sophia Children’s Hospital.
Transplantation Procedure
The protocols for specific conditioning regimens
were approved by the institutional review board of
our hospital. Written informed consent was obtained
from the parents and from both patients and donors
if older than 12 years. Patients with acute lymphoblas-
tic leukemia (ALL) received conditioning with either
the combination of busulfan (Bu), cyclophosphamide
(Cy), and etoposide (VP16) (BuCyVP16), or the regi-
men total-body irradiation (TBI) plus VP16 (TBI-
VP16). Patients with myeloid malignancies received
BuCy with or without melphalan (Mel). BuCy in
combination with antithymocytic globulin (Bu-
CyATG) was used as the preparative regimen in
patients with hemoglobinopathies. Patients treated
for aplastic anemia received Cy and ATG, whereas
fludarabine-based reduced-intensity conditioning
(RIC) was administered in patients with Fanconi ane-
mia. Thymoglobuline (Genzyme Europe B.V Naar-
den, the Netherlands) 10 mg/kg total dose was
added to the preparative regimen in all patients who
underwent allo-HSCT from a volunteer unrelated
donor (VUD). Fifty-six patients received either T
cell–depleted (mismatsched HLA donors) or partially
T cell–depleted grafts (in VUD-SCT when T cell
number of the grafts .2  108/kg). Prophylaxis
against aGVHD consisted of cyclosporine A and
methotrexate in all patients who received unmanipu-
lated bone marrow (BM) or peripheral blood stem cell
(PBSC) grafts. Methotrexate was omitted in cases
where the graft was either cord blood or T cell-
depleted BM.
Treatment of aGVHD—Definitions
The diagnosis and grading of aGVHDwasmade as
previously described by consensus criteria [13]. Skin
and oral mucosa involvement was diagnosed on the ba-
sis of the presence of a maculopapular skin rash and
oral mucosal inflammation, with an appropriate histo-
pathologic examination whenever necessary. Liver in-
volvement was evaluated when the serum bilirubin
level was elevated to 2.0 mg/dL or higher, and this
could not be explained by other causes such as liver
veno-occlusive disease (VOD), drugs, sepsis, hepatitis,
hemolysis, or biliary tract obstruction. Patients with
concomitant skin and/or liver involvement were
determined to have GI-aGVHD when diarrhea of
Table 1. Patient Characteristics and Transplant Outcomes
All Patients
(n 5 300)
GI-aGVHD Patients
(n 5 46)
Sex (F/M) 140/160 21/25
Median age, years (range) 8 (0.4-23) 10.33 (0.5-23)
Sex (donor to recipient)
Female to male 76 10
Diagnosis
Hemoglobinopathies 102 12
ALL 89 13
Myeloid malignancies 54 11
Immunodeficiencies 20 6
Aplastic syndromes 16 3
Others 19 1
Conditioning
Non–TBI-based 264 42
TBI-based 36 4
Including ATG 190 25
Donor type
HLA-identical sibling 206 32
VUD 84 13
Mismatched related 10 1
Stem cell source
BM 231 34
PBSC 45 7
CB 16 4
BM + CB 8 1
Alive 222 30
Causes of death
Relapse 43 2
Nonrelapse 35 14
1060 Biol Blood Marrow Transplant 17:1058-1066, 2011E. Goussetis et al..10mL/kg/day was present in the absence of an infec-
tious etiology such as viral, mycotic, and parasitic
pathogens. In 31 out of 46 patients with GI-
aGVHD, diagnosis was confirmed by histologic exam-
ination, whereas for the rest, the presence of refractory
thrombocytopenia did not allow us to perform endos-
copy. and the diagnosis of GI-aGVHD was based on
clinical and laboratory findings. Polymerase chain re-
action (PCR) testing for the presence of cytomegalovi-
rus (CMV) DNA in stool samples was performed in all
patients with gastrointestinal symptoms. Patients with
suspected gastrointestinal involvement including
symptoms of upper and lower gastrointestinal tract
but without skin or liver involvement were determined
to have GI-aGVHD if characteristic pathologic find-
ings on biopsy were present [20]. The day of onset of
aGVHD was defined as the date of initiation of sys-
temic immunosuppressive therapy. Response to treat-
ment was evaluated by the attending physician and
prospectively recorded in the patient’s file. Complete
resolution (CR) of aGVHDwas defined as the absence
of all signs and symptoms in all affected organs,
whereas partial response (PR) was defined as an im-
provement of 1 stage in 1 or more organs without pro-
gression in any other organ. No response was defined
as absence of improvement or deterioration within
a predefined time frame of therapy initiation. Progres-
sion was defined as worsening by 1 or more stages in
any involved organ. CR for gastrointestinal involve-ment was defined as \10 mL/kg/day stool volume
and absence of nausea/vomiting. A PR was defined as
an improvement of 1 stage (10 mL/kg) in stool output
per day or more.
Primary treatment for aGVHD consisted of meth-
ylprednisolone (MP) 2 mg/kg per day for 7 or 14 days,
followed by gradual dose reduction in responding
patients. Treatment with calcineurin inhibitors and
standard supportive care were administered through-
out the course of GVHD. In cases where no response
or even progression was observed after 7 days of pri-
mary treatment, MP dose was escalated to up to 5
mg/kg/day until day 14. Patients with no response
(neither CR nor PR) or with progression by day 14
were considered as having steroid refractory aGVHD
and were eligible for salvage therapy. Salvage treat-
ments consisted of: (1) ATG (Thymoglobulin) 15
mg/kg total dose combined with MP, (2) infliximab,
(3) extracorporeal photopheresis, (4) mycophenolate
mofetil, and (5) mesenchymal stem cell infusions.
Serum albumin levels were measured daily in pa-
tients treated for aGVHD, especially in cases with
GI involvement. Day 0 was defined as the day of ste-
roid treatment initiation. It is our standard practice
to consider administration of albumin concentrate in-
fusions to every patient with a serum albumin level be-
low 3 mg/dL, in order to avoid development of edema
and fluid restriction. Therefore, the level of 3 mg/dL
was chosen as the cutoff for further stratification of
patients regarding serum albumin levels.Statistical Analysis
The primary endpoint of this retrospective study
was to analyze the association between various prog-
nostic factors with response to GVHD treatment (at
day 114 after initiation of treatment), NRM, and OS
in patients with GI-aGVHD. Time to GVHD was
considered as the time from the day of stem cell infu-
sion to onset of GVHD. Time to NRM was defined
as the time from the day of onset of GI-aGVHD to
death not related to progression/relapse, or last
follow-up. OS was defined as the time from the day
of onset of GI-aGVHD to death from any cause, or
last follow-up. Event-free patients were censored at
the time of last follow-up.
OS estimations were made according to the
Kaplan-Meier method. It is important to note that
death because of relapse/progression is a competing
risk to NRM and development of GVHD. Competing
risk was taken into consideration when estimating the
cumulative incidence rates of NRM and GVHD.
R-software was used for estimation of cumulative
incidence rates in the presence of competing risk
[21]. Univariate analysis of prognostic factors was
made according to the log-rank test. All prognostic
variables with a significance level #0.1 were included
Figure 1. Cumulative incidence of aGVHD grade II-IV.
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wise Cox proportional hazards regression model [22].
Patients with GI-aGVHDwho achieved CR or PR
by day 114 were considered as responders to steroid
treatment. Patients who died before day 114 were
considered as nonresponders to steroids. The associa-
tion of various baseline variables with response to ste-
roids was examined using logistic regression analysis
[23,24]. All comparisons were 2-tailed and a P # .05
was considered significant.
The following prognostic factors were included in
our analysis: (1) disease type (malignant disorder ver-
sus not), (2) age of the recipient (above versus below
the median), (3) age of the donor (above versus below
the median), (4) sex of the recipient (male versus fe-
male), (5) female donor to male recipient (yes versus
no), (6) type of donor (related versus unrelated), (7)
source of stem cells (bone marrow versus peripheral
blood versus cord blood), (8) HLA match (fully
matched versus not), (9) ATG as part of the condition-
ing regimen (yes versus no), (10) TBI as part of the
conditioning (yes versus no), (11) serum albumin level
at the onset of GI-GVHD (above versus below me-
dian), (12) serum albumin level on day 15 after onset
of steroids (above or equal to 3 mg/dL versus below
3 mg/dL), and (13) year of SCT (before versus after
January 2004).
The statistical significance of serum albumin level
(day 15) was further tested using receiver-operating
characteristic (ROC) analysis. In more detail, ROC
analysis was performed to determine an optimal cutoff
value of serum albumin (day 15) in predicting re-
sponse to steroids, NRM, and OS in patients with
GI-aGVHD.
The year of SCT was included in the present anal-
ysis, because in a previous unpublished analysis of our
data, we observed a significant impact of the year of
SCT on clinical outcome. Briefly, patients trans-
planted after 1/2004 had decreased NRM in compari-
son with patients who underwent SCT before 1/2004.RESULTS
Cumulative Incidence of aGVHD
Overall, 133 out of 300 patients developed
aGVHD grade II-IV at a median time of onset of 24
days (range: 10-90 days). In more detail, 88 and 45 pa-
tients developed grade II, and grade III-IV, respec-
tively. The cumulative incidence of aGVHD grade
II-IV was 42,8% (Figure 1). Skin, gastrointestinal,
and liver involvement was observed in 121 (91%), 46
(35%), and 12 (9%) of the 133 patients with aGVHD,
respectively. Skin was the only organ affected in 82/
133 (62%) of patients, whereas in 40/133 (30%) skin
in combination with another organ was involved.
Nonskin aGVHD with single-organ involvement wasdiagnosed as isolated GI or liver-GVHD in 6/133
(4.5%) and 4/133 (3%) of the cases, respectively. We
examined the association of the following prognostic
factors with aGVHD (grades II-IV), and GI-aGVHD:
(1) disease type, (2) age of the recipient, (3) age of
the donor, (4) female donor to male recipient, (5)
type of donor, (6) source of stem cells, (7) HLA match
(8) ATG included in the preparative regimen, (9) TBI
included in the preparative regimen, and (10) year of
transplant (before versus after 2004) (for details, see
Statistical Analysis).
In multivariate analysis, age of the donor (above
the median) (P \ .001, hazard ratio [HR] 5 1.862,
95% confidence interval [CI] [1.292-2.684]) and allo-
SCT for malignant disease (P\ .001, HR 5 2.478,
95% CI [1.472-4.171]) were statistically significantly
associated with an increased hazard of aGVHD, grade
II-IV.
Forty-six out of 300 patients developed GI-
aGVHD at a median time of onset of 22 days (range:
11-90 days). In more detail, 37 patients had evidence
of only lower GI-tract involvement, whereas 6 had
both upper and lower GI tract, and 3 had only upper
GI tract involvement, respectively. The cumulative
incidence of GI-aGVHD was 15.1% (Figure 2). In
multivariate analysis, age of the donor above the me-
dian was the only variable associated with increased
risk of GI-aGVHD (P 5 .007, HR 5 2.395, 95% CI
[1.261-4.550]).
Patients with aGVHD: Comparison of Patients
With and Without GI Involvement
Patients were divided into 2 groups: Group 1 con-
sisted of patients with acute GI-aGVHD, whereas
Group 2 consisted of patients with aGVHD but with-
out gastrointestinal involvement. The time of onset of
GVHD was not different between the 2 groups. We
performed multivariate analysis, using a Cox regres-
sion proportional hazard model, in order to find
Figure 2. Cumulative incidence of GI-aGVHD.
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volvement among patients with aGVHD. None of the
variables, mentioned under the section Statistical
Analysis, was significantly associated with GI involve-
ment.
NRM was significantly increased in the group of
patients with GI-GVHD (P 5 .021), compared with
the group of patients without GI involvement. How-
ever, relapse of the original disease was more frequent
in the group of patients without GI-GVHD (P 5
.013), and finally, OS was not different between the 2
groups of patients (P 5 .79) (data not shown).Figure 3. Receiver-operator characteristics analysis. The association
of serum albumin levels (day 15) with response to steroids in patients
with GI-aGVHD.Response to Treatment with Steroids in Patients
with GI-aGVHD
Initially, all 46 patients received treatment with
MP 2-5 mg/kg/day for 14 days. Twenty-four out of
46 patients did not show any response by day114 after
initiation of treatment, and they were considered as
nonresponders to treatment with steroids. Salvage
treatment for patients with no response to steroids
was as follows: ATG in 16, infliximab in 2, higher
doses of steroids (20 mg/kg) plus octreotide in 2, my-
cophenolate mofetil plus extracorporeal photopheresis
in 2, and tacrolimus plus mesenchymal stem cell infu-
sions in 2 of the 24 patients, respectively. Fourteen out
of 24 patients who received salvage therapy experi-
enced successful control of aGVHD in a median of
34 days (range: 21-65 days) after initiation of primary
therapy, whereas in 10 patients GVHD was refractory
to any therapy. In 11 out of 46 patients, the initial daily
dose of MP was escalated to 5 mg/kg because of inad-
equate response by day 17 after initiation of treat-
ment. Therefore, the dose of steroids (2 mg/kg
versus 5 mg/kg) during initial treatment was included
in statistical analysis as a variable. In total, 22 out of
46 patients responded to steroid treatment by day114.Using ROC analysis, an optimal cutoff value of se-
rum albumin (day 15) of 3 mg/dL was a significant
predictor of response to steroid treatment with posi-
tive predictive value (PPV) 5 65%, and negative
predictive value (NPV) 5 87%, (area under the ROC
curve 5 0.725, P 5 .002) (Figure 3). In more detail,
the group with serum albumin at day 15 below 3
mg/dL consisted of 15 patients with mean serum albu-
min 2.76 mg/dL (range: 2.1-2.9, SD 5 0.25), and
among them, only 2 responded to first-line treatment
with steroids. In contrast, group with serum albumin
at day 15 above or equal to 3 mg/dL, consisted of 31
patients with mean serum albumin 3.7 mg/dL (range:
3.0-4.5, SD 5 0.44), and among them, 20 responded
to first-line treatment with steroids. Serum albumin
levels at day 15 in different cohorts of patients are
shown in Table 2.
The association of various parameters (mentioned
under the section statistical analysis) with the possibil-
ity of achieving a response to steroids was examined
using stepwise logistic regression analysis. Patients
with 1 of the following characteristics had an in-
creased likelihood of achieving a response to steroids:
(1) age of the donor below the median, (2) ATG
as part of the conditioning regimen, (3) matched re-
lated donor, and (4) serum albumin level $3 mg/dL
on day 15 after the onset of GI-GVHD (Table 3).
None of the rest of the variables, including the initial
dose of steroids (2 mg/kg versus 5 mg/kg), had any
statistically significant association with response to
steroids.
Table 2. Serum Albumin Levels (Day +5) in Different Cohorts of Patients
Groups of Patients
Initial Treatment
with MP* 2 mg/kg
Initial Treatment
with MP* 5 mg/kg
Responders to
Steroids by Day +14
Nonresponders to
Steroids by Day +14
Number of patients 35 out of 46 11 out of 46 22 out of 46 24 out of 46
Albumin, mg/dL
mean, range
3.38 (2.3-4.5) 3.49 (2.1-4.4) 3.61 (2.9-4.4) 3.19 (2.1-4.5)
Standard deviation .57 .64 .51 .60
Statistical significance P 5 ns P 5 .008
GI-GVHD indicates gastrointestinal graft-versus-host disease; ALL, acute lymphoblastic leukemia; BM, bone marrow; PBSC, peripheral blood stem cell;
CB, cord blood; TBI, total-body irridiation; ATG, antithymocyte globulin; VUD, volunteer unrelated donor.
*MP indicates methylprednisolone.
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Gastrointestinal Involvement
Overall, 14 out of 46 patients died because of
reasons unrelated to relapse of the original disease at
a median time of 5.2 months (range: 1.4-45.5 months).
The cumulative incidence of NRM at 5 years was 33%
(95% CI, 19%-48%). With a median follow-up of 42
months (range: 2-160), 30 out of 46 patients are alive,
whereas 10 patients died because of aGVHD-related
complications, 4 patients because of infections, and 2
patients died because of relapse of underlying malig-
nancy. The probability of OS at 5 years was 62%
(95% CI, 48%-76%).
We performedmultivariate analysis to examine the
impact of the variables, mentioned under the section
statistical analysis, on NRM and OS in patients treated
for GI-aGVHD. The following variables were found
to have no effect on NRM and OS: (1) age of the do-
nor, (2) age of the recipient, (3) sex of the recipient,
(4) ATG as part of the conditioning regimen, (5)
matched related donor, (6) serum albumin at the onset
of GI-GVHD, (7) severity of GVHD, (8) type of dis-Table 3. Variables Associated with Response to Treatment, NR
Involvement
Variables Predictive of Response to Treatment w
Variables
Age of the donor, above vs. below the median
Low albumin vs. high albumin (3 mg/dL on day +5 after onset of treatment)
ATG as part of the conditioning, no versus yes
VUD versus MRD
Variables Associated with NRM in Patients Treated for aGVHD with Ga
Variables
Low albumin versus high albumin (3 mg/dL on day +5 after onset of treatment)
Response to steroids, no versus yes
Variables Associated with OS in Patients Treated for aGVHD with Gas
Variables
High albumin versus low albumin (3 mg/dL on day +5 after onset of treatment)
Response to steroids, no versus yes
OS indicates overall survival; NRM, nonrelapse mortality; CI, confidence inte
aGVHD, acute graft-versus-host disease; ATG, antithymocyte globulin.ease, (9) TBI as part of the conditioning, (10) source
of stem cells, (11) HLA match, (12) year of transplant,
and (13) initial dose of steroids.
In multivariate analysis, patients with serum albu-
min levels above or equal to 3 mg/dL on day 15 after
the onset of GVHD and a favorable response to
treatment with steroids had a decreased hazard of
NRM (Table 3 and Figure 4). Similarly, multivariate
analysis showed that, serum albumin levels above or
equal to 3 mg/dL (day 15 after the onset of GVHD)
and a favorable response to treatment with steroids,
were statistically significantly associatedwith improved
OS (Table 3 and Figure 5).DISCUSSION
There have been no prior reports that specifically
address the incidence and outcome of gastrointestinal
aGVHD in children. The majority of the published
data regarding this particular complication comes
from adult studies. Very few available data concerning
children come from either the pediatric subset of largeM, and OS in Patients with aGVHD and Gastrointestinal
ith Steroids. Stepwise logistic Regression
Statistical Significance Odds Ratio 95% CI
P 5 .029 .128 .020-.819
P 5 .036 .065 .005-.838
P 5 .026 .031 .001-.661
P 5 .003 .003 .0001-.157
strointestinal Involvement. Cox Proportional Hazards Regression
Statistical Significance HR 95% CI
P 5 .021 4.064 1.237-13.352
P 5 .029 4.316 1.164-16.002
trointestinal Involvement. Cox Proportional Hazards Regression
Statistical Significance HR 95% CI
.026 3.432 1.161-10.136
.011 5.329 1.472-19.289
rval; VUD, volunteer unmatched donor; MRD, matched related donor;
Figure 4. Patients with GI-aGVHD: the impact of serum albumin level
(day 15 after onset of treatment) on NRM.
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study, the cumulative incidence of GI-aGVHD was
15% and not different from previous pediatric studies
where incidence ranged from 7.2% to 39% [25,26].
The current reference standard for diagnosis and
staging of GI-aGVHD combines assessment of clini-
cal symptoms with histologic examination of mucosal
biopsy specimens obtained by endoscopy of the upper
and/or lower intestinal tract. In clinical practice, how-
ever, transplant physicians are reluctant to perform en-
doscopy in all pediatric patients presenting with
gastrointestinal manifestations because of concerns re-
garding the safety of the procedure. In such cases, the
diagnosis of gastrointestinal involvement by aGVHD
is clinical and requires extensive evaluation to rule
out other causes of GI symptoms. Endoscopy studies
and histologic examination of mucosal biopsies were
performed in 31 out of 46 patients diagnosed with
GI-aGVHD, and indeed, in all these patients, clinical
diagnosis was confirmed histologically. Endoscopy
and histologic diagnosis were not performed in theFigure 5. Patients with GI-aGVHD: the impact of serum albumin level
(day 15 after onset of treatment) on OS.rest of the patients because of the presence of refrac-
tory thrombocytopenia. However, all of these patients
had a clinical presentation compatible with GI-
aGVHD, with either skin or liver involvement and
without evidence of another pathologic entity respon-
sible for gastrointestinal symptoms. More specifically,
infectious causes of diarrhea were ruled out through an
extensive microbiology workup. Stool samples were
examined repeatedly for the presence of pathogenic
bacteria, parasites, and viruses. CMV enteritis was ex-
cluded by PCR testing for CMVDNA in stool samples
[27,28]. In multivariate analysis, age of the donor
above the median and allo-SCT for a malignant disor-
der were significantly associated with increased hazard
of aGVHD development. When analysis was re-
stricted to the cohort of patients with GI-GVHD,
then age of the donor above the median was the only
variable significantly associated with increased hazard
of GI involvement.
Response to initial treatment with steroids is the
most significant factor associated with improved out-
come in patients with aGVHD. Complete responses
occur in 30% to 50% of patients, and in those with
a complete response, 5-year OS is approximately
50%, as opposed to 5-year OS of \20% in those
with no or incomplete response [29]. Current grading
systems of aGVHD, reflecting the overall disease se-
verity, have been used with the aim to predict which
patients will respond to therapy. It seems, however,
that GVHD grade is not a reliable tool for predicting
response to prednisone therapy [30]. In a prospective
study of 211 patients with aGVHD (grades I-IV),
NRM of 27% was observed in patients responding to
2 mg/kg prednisolone within 5 days, whereas NRM
of 49% was observed in the group of nonresponders.
In this study, an improvement in the grade of
GVHD 5 days after treatment with concurrent reduc-
tion in steroid dose was used as the major response cri-
terion [31]. However, in patients with gastrointestinal
involvement, there is usually a significant delay from
termination of the intestinal inflammation until the
restoration of intestinal function. In accordance with
the previous data, we and others consider that it is
not reasonable to rely only on the daily amount of
stools for assessment of response to treatment in cases
of intestinal involvement [14,32]. The need for an
objective way to measure the activity of GI-aGVHD
inflammatory process is obvious, because it will define
the time for second-line treatment administration. In
this direction, few studies have attempted to correlate
GVHD histology to outcome. Socie et al. [33], in
a study with 95 patients who underwent gastroduode-
nal biopsy, showed that the degree of neutrophil infil-
tration and the severity of apoptosis correlated with
NRM. They also reported that clinical grading itself
was not associated with transplant mortality. In
another study with 27 patients with GI-aGVHD, the
Biol Blood Marrow Transplant 17:1058-1066, 2011 1065Prognostic Predictors for Gastrointestinal aGVHDauthors showed that severe colonic crypt loss was
strongly associated with refractoriness of GI-aGVHD
to conventional steroid treatment, whereas response
assessment based on stool volume did not predict re-
fractory disease [19]. However, endoscopy and muco-
sal biopsies in these patients is not entirely free of
complications. A significant proportion of patients
are thrombocytopenic and/or neutropenic, and such
procedures are associated with an increased risk of
bleeding and infection. Endoscopic procedural lethal-
ity in transplanted patients has been reported as high as
1.8% [34].
In our study, we observed: (1) nonachievement of
any response after 14 days of primary treatment with
steroids is significantly associated with increased haz-
ard of NRM and decreased OS. In accordance with
our results, 2 recently conducted, large prospective
studies showed that achievement of response after 4
weeks of treatment is the most significant factor pre-
dictive of NRM and OS in patients treated for
aGVHD [35]. In our study, patients without any re-
sponse after 14 days of treatment had increased
NRM, suggesting that day 14 response evaluation
will be a useful tool to identify patients with very low
probability to benefit from continuation of primary
therapy, and therefore suitable for immediate adminis-
tration of second-line treatment [36]. (2) An interest-
ing finding of our study is the predictive value of
serum albumin levels. Serum albumin level below or
equal to 3 mg/dL on day 5 after the onset of treatment
was significantly associated with increased hazard of
NRM and decreased OS. Our findings suggest that
by using serum albumin levels, one can early identify
patients with low probability of response to steroid
treatment and high risk of NRM. If we consider that
the earlier the initiation of second-line treatment the
higher the possibility of therapeutic benefit, then it is
reasonable to assume that early identification of refrac-
tory patients is a prerequisite for a successful outcome.
Moreover, we consider that serum albumin is a more
reproducible and reliable parameter for response
assessment in comparison with daily stool volume esti-
mation. Hypoalbuminemia has been reported to occur
more frequently in association with severe aGVHD
and etiology is multifactorial. Hypoalbuminemia in
aGVHD without GI involvement is mainly because
of impaired synthesis and increased catabolism, which
are known to be associated with increased pro-
inflammatory cytokines [37]. However, cases with GI
involvement resemble protein-losing enteropathy,
and excessive intestinal loss of albumin is the major
factor resulting in hypoalbuminemia [38]. The prog-
nostic significance of serum albumin levels in patients
with aGVHD has been demonstrated in previous
studies. Lee et al. [23], in a retrospective analysis of
83 patients with aGVHD, showed that albumin levels
#2.8 g/dL at the onset of GVHD was significantlyassociated with increased hazard of treatment failure.
Similarly, in a recent retrospective study, authors
examined the impact of serum albumin levels on
transplant outcome in a cohort of 163 patients with
acute myelogenous leukemia/myleodysplastic syn-
drome (AML/MDS) who underwent allo-SCT. In
multivariate analysis, day 190 hypoalbuminemia was
significantly associated with increased NRM and
decreased OS [22].
Furthermore, we used ROC analysis in an attempt
to identify an optimal cutoff level of serum albumin
(day 15) that best predicted response to treatment
with steroids. Again, we observed that serum albumin
above or equal to 3 mg/dL was a significant predictor
of response to steroid treatment with PPV5 65%, and
NPV5 87%. Moreover the high NPV 5 87% is sup-
portive of a switch to a more aggressive treatment early
during the course of GI-aGVHD.
The observations of our study suggest that patients
with GI-aGVHD can be stratified into 2 groups with
different outcomes, as early as day 5 after the onset
of primary treatment. The significance of serum albu-
min level as a prognostic biomarker for patients with
aGVHD and gastrointestinal involvement needs to
be validated in future large prospective studies.ACKNOWLEDGMENTS
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